Aurobindo Pharma receives EIR from USFDA for Hyderabad facility

Aurobindo Pharma Limited stated that it has gained the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from US Food and Drug Administration (FDA) for Gaddapotharam facility at Hyderabad.

USFDA had earlier declared about the inspection of Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad.

Aurobindo Pharma Ltd is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company produces generic pharmaceuticals and active pharmaceutical ingredients. The domain of activity of company involves six major therapeutic/product areas such as anti-retrovirals, antibiotics, cardiovascular products, gastroenterologicals, central nervous system products and anti-allergics.